Hikma Pharmaceuticals (LON:HIK) Trading Down 14.1% Following Analyst Downgrade

Shares of Hikma Pharmaceuticals PLC (LON:HIK) dropped 14.1% on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares were traded during trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Several other equities research analysts also recently commented on HIK. Deutsche Bank Aktiengesellschaft reduced their target price on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a report on Tuesday, August 12th. JPMorgan Chase & Co. cut their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a report on Friday. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research report on Friday. Finally, Peel Hunt reiterated a “buy” rating and set a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a report on Friday. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of GBX 2,416.

Insider Activity at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Laura Balan Balan acquired 3,500 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average price of GBX 1,821 per share, with a total value of £63,735. Also, insider Mazen Darwazah acquired 315,000 shares of Hikma Pharmaceuticals stock in a transaction dated Thursday, November 6th. The stock was acquired at an average cost of GBX 1,601 per share, with a total value of £5,043,150. In the last quarter, insiders have acquired 332,500 shares of company stock worth $533,130,500. Corporate insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Stock Up 3.9%

The stock has a market capitalization of £3.50 billion, a P/E ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The firm’s fifty day moving average is GBX 1,730.88 and its 200-day moving average is GBX 1,893.97.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.